Site US10025 — Syracuse, New York

Site US10025 is a clinical research site located in Syracuse, New York, United States 13210.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Site US10025 has participated in 1 clinical trials.

Therapeutic areas: Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation.

Sponsors: Astellas Pharma Global Development, Inc..

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site US10025?

Site US10025 has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site US10025 conducted?

Site US10025 has 1 clinical trials on record. Their work covers Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation.

Is Site US10025 accredited by Crixeo Health?

Site US10025 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site US10025?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.